$33.76
-0.04-0.12%
At close: Nov 13, 4:00 PM EST
$33.60
-0.16-0.47%
After Hours: Nov 13, 4:00 PM EST
Harmony Biosciences Holdings Inc
HRMYNASDAQ
Harmony Biosciences Hldgs (HRMY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $0.81 | $1.37 | -40.9 % |
| Q2 | Aug 4, 2026 | $1.28 | $1.05 | 21.9 % |
| Q1 | May 7, 2026 | $0.55 | $0.90 | -38.9 % |
| Q4 | Feb 24, 2026 | $0.57 | $0.98 | -41.8 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $268.92M | $271.81M | -1.07 % |
| Q2 | Aug 4, 2026 | $261.30M | $242.15M | 7.91 % |
| Q1 | May 7, 2026 | $215.40M | $221.17M | -2.61 % |
| Q4 | Feb 24, 2026 | $243.78M | $241.47M | 0.95 % |
Harmony Biosciences Hldgs (HRMY) last issued guidance on November 4, 2026 for fiscal year 2026. The company guided revenue in the range of $1B - $1.04B for the period.
Compared to prior guidance, Harmony Biosciences Hldgs maintained its revenue forecast from a prior range of $1B - $1.04B.
Harmony Biosciences Hldgs has issued 24 guidance updates between January 8, 2024 and November 4, 2026. During this period, the company raised its outlook 4 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.37 | $1.05 | $0.90 | $0.98 |
| Actual | $0.81 | $1.28 | $0.55 | $0.57 |
| Surprise | -40.9% | +21.9% | -38.9% | -41.8% |
| Revenue | ||||
| Estimate | $271.8M | $242.1M | $221.2M | $241.5M |
| Actual | $268.9M | $261.3M | $215.4M | $243.8M |
| Surprise | -1.07% | +7.91% | -2.61% | +0.95% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.42 | $0.82 | $0.97 | $1.01 |
| Revenue | ||||
| Consensus | $282.4M | $257.9M | — | — |
